1. Won their Injunction
2. PreClinical Trials for its Immunotronics Platform
3. Filed for Orphan Drug Status
4. Over 20 patents
5. Form 4s filed by insiders
6. Converts being bought by Company and Institutions
7. Uplistment
8. President and CEO has been filing form 4's everyday so far the past couple weeks
$ENDV Upcoming Catalysts:
1. Pre-Clinical Studies To Be Completed in first quarter of 2017
2. Application for IND Orphan Drug Status for its Cytotronics Product
3. Over 20 Patent Applications OWNED by the CEO and the Company
4. 10 Form 4s filed since Dec 2016 for Insider purchases of stock
5. A "Strategic Healthcare" Institutional Investor has Ponied up $15...
Breakout past the 50DMA was a key point today. PARSAR flip Bolli and Ichimoku Cloud break. This move is mostly due to immense fundamentals at work and not an actual technical push, which is the best part, if you remember $OWCP this is similar in terms of fundamentals, but with much more potential and in term a much higher ROI. One of my 3 long term holds as of...
